Abstract
Introduction
Previously irradiated recurrent rectal cancer is a formidable patient threat with limited treatment options. Isolated pelvic perfusion (IPP) by the balloon-occlusion technique provides high-dose regional chemotherapy that may facilitate resection if appropriate or palliate pain and fungating tumor mass in the symptomatic patient. We currently report our results in 49 recurrent rectal cancer patients (26 had neoadjuvant IPP with intent to resect and 23 had IPP for palliation).
Methods
IPP was done for 1 hour with paclitaxel 30 mg/m2, 5 fluorouracil 1500 mg/m2, cisplatin/oxaliplatin 60-130 mg/m2, and mitomycin C 10 to 15 mg/m2 (the latter three achieving pelvic-to-systemic drug ratios of 6–9:1).
Results
Neoadjuvant perfusion in 26 patients achieved a response in 14 patients (made resectable). Seven had R0 resections (clear margins), six by abdominal sacral resection (ABSR), and one by an extended APR. Of seven other patients, one had a complete pathologic response negating planned resection, one had >50% tumor regression in pelvis (but developed distant metastases), and three refused ABSR. Planned ABSR in two patients was aborted because of complicating cardiovascular issues. A variety of medical and cancer issues precluded resection in the remaining 12 of these 26 neoadjuvant patients. Within the neoadjuvant group, median survival was 24 months in the responding (made resectable) group (14 patients) and it was 8 months in the non-resectable group (12 patients), p = 0.0001. In the responding (made resectable) group, seven patients had R0 resections (median survival 26 months) and seven patients were not resected (median survival 18 months), p = 0.0198. In the IPP group for palliation, 17 of 23 patients (74%) had significant relief of pain, and other tumor-related symptoms (mean survival 11 months).
Conclusion
Isolated pelvic perfusion using a simplified balloon-occlusion technique has promise in palliation of or augmenting resectability of advanced rectal malignancy in patients not amenable to treatment with conventional modalities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: Regional perfusion utilizing an extra corporeal circuit. Ann Surg 1958; 148:616–32
Watkins E Jr, Hering AC, Luna R, Adams HD. The use if intravascular balloon catheters for isolation of the pelvic bed during pup oxygenator perfusion of cancer chemotherapeutic agents. Surg Gynecol Obstet 1960; 111:464–8
Wile A, Smolin M. Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer. Arch Surg 1987; 122:1321–5
Turk PS, Belliveau JF, Darnowski JW, et al. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 1993; 128:533–6
Wanebo HJ, Chung MA, Levy AI, Turk PS, Vezeridis MP, Belliveau JF. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with balloon-occlusion technique. Ann Surg Oncol 1996; 3:295–303
Wanebo HJ, Belliveau JF. A pharmacokinetic model, and the clinical pharmacology of cis-platinum, 5-flourouracil and mitomycin-C in isolated pelvic perfusion. Cancer Chemother Pharmacol 1999; 43:427–34
Hoekstra HJ, Naujocks T. Koops HS, et al. Continuous leaking monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Reg Cancer Treat 1992; 4:301–4
Lejeune FJ, Lienard D, Leyvraz S, et al. Regional chemotherapy of melanoma. Eur J Cancer 1993; 294:606–12
Thom AK, Alexander Hr, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995; 13:264–73
Muchmore JH, Krementz ET, Carter RD, Preslan JE, George WI. Treatment of abdominal malignant neoplasms using regional chemotherapy with hemofiltration. Arch Surg 1991; 126:1390–6
Turk PS, Wanebo HJ, Belliveau J, et al. Hemofiltration vs. charcoal hemoperfusion for venous extraction of regional chemotherapy. Manuscript submitted
Miller DG, Lawrence W. Bone marrow protection in mechlorethamine (nitrogen mustard) therapy. Arch Surg 1962; 85: 430–41
Nord LD, Stolfi RL, Martin DS. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: correlation of antitumor activity with dosage and Fura incorporation into RNA. Biochem Pharmacol 1992; 43:2543–9
Delaney M, Stancu M, Begossi G, Elfenbein GJ, Wanebo HJ. Neoadjuvant therapy with high dose chemotherapy via isolated pelvic intra-abdominal perfusion with bone marrow stem cell support for advanced endometrial cancer. Med Health Rhode Island 2003; 86(8):252–5
Dedrich RL. Arterial drug infusion: Pharmacokinetic implications: problems and pitfalls. Cancer 1986; JNCI80:84–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wanebo, H.J., DiSiena, M., Begossi, G. et al. Isolated Chemotherapeutic Perfusion of Pelvis as Neoadjuvant or Palliative Therapy for Advanced Cancer of the Rectum. Ann Surg Oncol 15, 1107–1116 (2008). https://doi.org/10.1245/s10434-007-9652-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-007-9652-9